Drug Response Dx

Drug Response Dx is a biotechnology company located in Hennigsdorf, Germany, founded in February 2012 by a team of experts including Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner, and Dr. Joachim Rautter. The company specializes in developing biomarker tests specifically designed to evaluate treatment outcomes for rheumatoid arthritis (RA). Its tests focus on a protein that predicts the effectiveness of TNF-alpha inhibitors for individual patients prior to initiating medication. This approach facilitates timely treatment decisions and enhances the likelihood of successful therapeutic outcomes for patients suffering from RA. The company has established proof of concept using serum samples from RA patients, and its biomarker set is prevalidated, ensuring the reliability of its testing processes.